Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
Article Information
vol. 39 no. 10 1702-1710
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 30, 2016
- Accepted July 16, 2016
- Published in print September 22, 2016.
- Published online ahead of print August 9, 2016.
Article Versions
- Previous version (August 9, 2016 - 07:15).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2016 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
Author Information
- Chantal Mathieu1⇑,
- Bernard Zinman2,
- Joanna Uddén Hemmingsson3,
- Vincent Woo4,
- Peter Colman5,
- Erik Christiansen6,
- Martin Linder6 and
- Bruce Bode7,
- for the ADJUNCT ONE Investigators*
- 1Gasthuisberg Hospital, University of Leuven, Leuven, Belgium
- 2Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
- 3Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
- 4Health Sciences Centre, Winnipeg, Manitoba, Canada
- 5Royal Melbourne Hospital, Parkville, Victoria, Australia
- 6Novo Nordisk A/S, Bagsværd, Denmark
- 7Atlanta Diabetes Associates, Atlanta, GA
- Corresponding author: Chantal Mathieu, chantal.mathieu{at}med.kuleuven.be.
Statistics from Altmetric.com
Article usage
In this Issue
October 2016, 39(10)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
